Understanding the Regeneron Pharmaceuticals Class Action
Levi & Korsinsky, LLP, a renowned law firm, has reached out to investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to inform them about an ongoing class action securities lawsuit. This initiative aims to address significant losses experienced by shareholders during a specific period, addressing pressing issues in the company’s operations and disclosures.
Details of the Class Action
The class action principally seeks to recover losses incurred between November 2, 2023, and October 30, 2024. Investors affected during this timeframe may find solace in participating in this lawsuit. The legal action stems from allegations of securities fraud that potentially misled investors regarding Regeneron’s business practices.
Key Allegations Against Regeneron
The complaint outlines critical points, indicating that Regeneron engaged in practices that misrepresented its financial health and operational transparency. It claims that the company allegedly made misleading statements about its credit card fee payments to distributors concerning the sale of its flagship product, Eylea. This included undisclosed arrangements that effectively subsidized the medication's price through credit card purchase incentives.
Your Rights as an Investor
If you invested in Regeneron during the defined period and believe you suffered losses, now is the time to act. The deadline to request your appointment as lead plaintiff is March 10, 2025. Importantly, participation does not mandate you to serve as lead plaintiff to share in any recovery outcomes.
What to Expect If You Participate
Joining the class action comes with no financial burden. As a class member, any compensation secured through the lawsuit will not require any fees or out-of-pocket costs from you. The process is designed to ensure that investors can seek justice and potential recovery without additional financial strain.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has cultivated a powerful reputation over the past two decades, securing hundreds of millions of dollars for investors across various complicated cases. With a dedicated team of more than 70 professionals, the firm excels in navigating the complexities of securities litigation. Its consistent recognition in ISS Securities Class Action Services' Top 50 Report further solidifies its standing in the legal landscape.
Contact Information
If you are interested in participating in this class action or wish to learn more about your rights, reach out to Levi & Korsinsky directly. Joseph E. Levi, Esq. and Ed Korsinsky, Esq. lead the team committed to helping investors through this legal process.
For inquiries, you can contact the firm via telephone:
Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Frequently Asked Questions
What is the purpose of the class action lawsuit?
The class action aims to recover losses incurred by investors due to alleged misleading information by Regeneron Pharmaceuticals about their business practices.
Who is eligible to participate?
Investors who acquired shares of Regeneron between November 2, 2023, and October 30, 2024, may be eligible to join the class action.
How much will it cost to join?
Joining the class action will incur no costs for participants. Investors may be entitled to compensation without payment of out-of-pocket expenses.
What are the next steps for interested investors?
Investors should contact Levi & Korsinsky before the March 10, 2025 deadline to potentially become part of the legal action.
Why should I choose Levi & Korsinsky for my representation?
Levi & Korsinsky is recognized for effectively advocating for shareholders with a strong track record in securities litigation. Their expertise increases the likelihood of positive outcomes for investors.
